On Friday 15th September, the groupH core team and local associates met in London for an end-of-summer social get together. At our dinner in Notting Hill, we celebrated togetherness, successfully completed projects, catching up on personal news and the fact that luck was on our side with glorious late-summer weather throughout the day.
Friday, 27 October 2023 at 13:00 UK (14:00 CET)
Register here
As a student already, Fritz Meyer has been interested in quantitative marketing, economics and epistemology. Forecasting projects have always been fascinating to Fritz, as forecasts have consequences. Every forecast is different for him based on the concrete business question. During his more than 20 years in global forecast functions he has created many forecast models over many disease areas to support decisions from short planning to long term investments, from smaller decisions to large mergers. Fritz is currently forecasting a number of different products at Boehringer Ingelheim. He holds an MBA (University of Hamburg), a master in economic epistemology (Paris I/ENS d’Ulm) and a master in Market Access (EMAUD University Bordeaux). In his spare time Fritz enjoys running and playing chess.
The halo effect was first identified by psychologist Edward Thorndike in the 1920ies. It describes the tendency to make specific interference based on a general impression. The halo effect on sales can be positive and negative. Nowadays in pharmaceutical forecasting the halo effect is cited on a regular basis to explain good performance and to predict superior product success. To show the halo effect, we will look on several examples in pharma and in a second step the „right“ questions are proposed before forecasting new products or evaluate existing products. There will be ample time in the subsequent Q&A and forum discussions to address questions such as ‘Can a halo effect be quantified in a forecast?’ and to hear from your peers in the industry what they have to say about this topic.
Target audience: Insights Analysts, Forecasters, Marketeers and Value Leads who need to understand which factors and events will impact on their revenue forecast positively or negatively.
Any questions just get in touch:
groupH’s discussion on TPP Development and Indication Prioritization took place at the NPP Summit Boston on October 16, 2023.
Erik Holzinger and Iain Clark talked through 2 project case studies focusing on pre-clinical or early-stage clinical stage by sharing client views on project timing and project learnings.
Please click on the here to view document.
NPP Summit_TPP Development and Indication Prioritization PDF
groupH has analysed what is known about the Inflation Reduction Act (IRA) of 2022, which constitutes a major legislative effort to address drug pricing and Medicare expenditure. We developed a simple easy-to-use model, which assesses the risk of any of the three parts of the IRA applying to a product that is either already on the market or still in development.
The IRA model has been developed based on primary market research with senior US market access experts and secondary analysis. The model and its associated white paper was first presented during the Fierce Biotech NPP Summit in Boston in October 2023.
Please click here to access the paper.
Please click on the image below to access the model.
groupH will talk through 2 project case studies focusing on TPP Development and Indication Prioritization for Biotech companies at pre-clinical or early-stage clinical stage. The talk is aimed at individuals in commercial and non-commercial roles who have to manage uncertainty when aligning on overall scientific and commercial strategy. We will discuss a recent, real-world project process and the trade-offs between different, alternative project approaches. We will dissect the TPP development process and share client views on project timing and project learnings. Participants will leave with key insights from this real-world technology platform development project and there will be time for Q&A at the end.
About Erik Holzinger, groupH:
Erik Holzinger MBA is the founder of groupH a Consulting company dedicated to commercial decision making and analysis. In recent years Erik has been particularly interested in exploring the topics driving TPP development at the more delicate, early stages when commercial and scientific uncertainty is still quite high. Erik is also active as member of the ephmra Annual Conference Organising Committee and co-founder of the ephmra Forecasting Forum. Prior to 2005, he was a Principal Consultant in the Pharmaceuticals and Biotechnology team of Wood Mackenzie and a Consultant at The Wilkerson Group. His mother tongue is German, and he is fluent in English and Spanish and lives in South-West London with his family. Outside of work Erik enjoys spending time with his family, yoga, cycling, windsurfing, skiing and the cultural landscape of London.
Find out more about the NPP Summit Boston, October 16, 2023:
Register for the event: https://www.newproductplanning.com/newproductplanningcom/register
See full list of speakers: https://www.newproductplanning.com/newproductplanningcom/faculty
View full programme: https://www.newproductplanning.com/newproductplanningcom/schedule
Any questions just get in touch – erik.holzinger@grouph.com
